The 6th ISCC

November 13 -14, 2001
Yurakucho Asahi Hall

November 13, 2001 (Tue)

13:00 - 13:10

Haruo Sugano (Cancer Chemotherapy Center, Tokyo)

Welcome and Introduction

I Drug development based on genome sequencing and expression profiling

Chairpersons: Ivan Horak (Pharmacia, Co., Peapack, NJ)
Yusuke Nakamura (Univ. Tokyo, Tokyo)

13:10–13:40

Susan Holbeck (NCI, Bethesda, MD)

The NCI 60 human tumor cell line panel : A tool linking molecular targets to drug sensitivity

13:40–14:10

Mark J. Ratain (Univ. Chicago, Chicago, IL)

Pharmacogenetics of anticancer agents

14:10–14:30

Hiroshi Sugiyama (Tokyo Medical and Dental Univ., Tokyo)

Sequence-specific alkylating polyamide as a tailor-made antitumor agent

14:30–14:45

Discussion

14:45–15:05

Coffee Break

II Angiogenesis Inhibitors and Antimetastatic Agents

Chairpersons: Herbert M. Pinedo (Free Univ., Netherlands)
Saburo Sone (Univ. Tokushima, Tokushima)

15:05–15:35

Raffaella Giavazzi (Mario Negri Institute, Bergamo, Italy)

Angiogenesis inhibitors in combination therapy

15:35–15:55

Kazuhiko Yonekura (Taiho Pharmaceutical, Co., Saitama)

Preclinical efficacy of TSU-16 and TSU-68

15:55–16:25

Eric Holmgren (Genentech, Inc., South San Francisco, CA)

Anti-VEGF antibody : Clinical experience in Phase II trials

16:25–16:40

Discussion

III Drugs Targeted at Specific Gene Function in Tumors (Part I)

Chairpersons: Jean P. Armand (Institut Gustave-Roussy, Villejuif, France)
Ryuzo Ueda (Nagoya City Univ., Nagoya)

16:40–17:10

Ivan Horak (Pharmacia, Co., Peapack, NJ)

Molecular targets for therapeutic intervention; Are we ready?

17:10–17:40

Ross C. Donehower (Johns Hopkins Univ., Baltimore, MD)

Alteration of gene expression as a strategy for cancer treatment

17:40–18:00

Discussion

18:00–19:00

Mixer

November 14, 2001 (Wed)

IV Drugs Targeted at Specific Gene Function in Tumors (Part II)

Chairpersons: Edward A. Sausiville (NCI, Bethesda, MD)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)

10:00–10:30

Peter Elliott (Millennium Pharmaceuticals, Cambridge, MA)

Clinical development of the proteasome inhibitor, PS-341

10:30–10:50

Akihiro Tomida (Univ. Tokyo, Tokyo)

Proteasome inhibitors in cancer chemotherapy

10:50 - 11:10

Kazuhiko Nakagawa (Kinki Univ., Osaka)

Farnesyltransferase inhibitor R115777

11:10–11:30

Saburo Sone (Univ. Tokushima, Tokushima)

EGFR tyrosine kinase inhibitor ZD1839

11:30–12:00

Matthias Mueser (Merck, Darmstadt, Germany)

Treatment of cancer with cetuximab, an anti-EGFR monoclonal antibody

12:00–12:20

Nagahiro Saijo (National Cancer Center Hosp., Tokyo)

CPT-11 in the treatment of SCLC

12:20–12:35

Discussion

12:35–13:30

Lunch Break

V Cancer-induced bone diseases: Mechanism and treatment

Chairpersons: Raffaella Giavazzi (Mario Negri Institute, Bergamo, Italy)
Nagahiro Saijo (National Cancer Center Hosp., Tokyo)

13:30–14:00

Lance Liotta (NCI, Bethesda, MD)

Basic mechanism of cancer metastasis

14:00–14:30

John Shaughnessy (Donna and Donald Lambert Lab. of Myeloma, Little Rock, AK)

Global gene expression profiling in predictive therapy for multiple myeloma

14:30–15:00

Bart Barlogie (Arkansas Cancer Research Center, Little Rock, AK)

Toward curing myeloma–the Arkansas approach

15:00–15:30

Robert D. Rubens (Guys Hospital, London, UK)

Treatment of breast cancer metastasis to bone

15:30–15:45

Discussion

15:45–16:05

Coffee Break

VI Current Status in New Drug Development in Japan, Europe and the US

Chairpersons: Ross C. Donehower (Johns Hopkins Univ., Baltimore, MD)
Masahiro Fukuoka (Kinki Univ., Osaka)

16:05–16:35

Takashi Tsuruo (Univ. Tokyo, Tokyo)

International development of antitumor drugs in Japan

16:35–17:05

Jean P. Armand (Institut Gustave-Roussy, Villejuif, France)

New drugs in early development at the Institut Gustave-Roussy

17:05–17:35

Edward A. Sausiville (NCI, Bethesda, MD)

Novel molecular targets for cancer treatment under development by NCI

17:35–17:50

Discussion

Closing Remark

17:50 - 18:00

Takashi Tsuruo (Univ. Tokyo, Tokyo)

Page TOP